



Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort

Ariane Vienne, Tabassome Simon, Jacques Cosnes, Clotilde Baudry, Yoram Bouhnik, Jean-Claude Soule, Stanislas Chaussade, Philippe Marteau, Raymond Jian, Jean-Charles Delchier, et al.

► To cite this version:

Ariane Vienne, Tabassome Simon, Jacques Cosnes, Clotilde Baudry, Yoram Bouhnik, et al.. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. *Alimentary Pharmacology and Therapeutics*, Wiley, 2011, 34 (2), pp.188. <10.1111/j.1365-2036.2011.04711.x>. <hal-00645192>

HAL Id: hal-00645192

<https://hal.archives-ouvertes.fr/hal-00645192>

Submitted on 27 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort



Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0158-2011.R1
Wiley - Manuscript type:	Original Scientific Paper
Date Submitted by the Author:	05-Apr-2011
Complete List of Authors:	<p>VIENNE, Ariane; Cochin Hospital, Gastroenterology Simon, Tabassome; Saint Antoine Hospital, Pharmacology, URCEST Cosnes, Jacques; Saint Antoine Hospital, Gastroenterology Baudry, Clotilde; Saint-Louis Hospital, Gastroenterology Bouhnik, Yoram; AP-HP Hôpital Beaujon, Pole des maladies de l'appareil digestif, gastroentérologie et assistance nutritive SOULE, Jean-Claude; AP-HP, Hôpital Bichat, Service d'Hépatogastroentérologie Chaussade, Stanislas; Cochin Hospital, Gastroenterology Marteau, Philippe; Lariboisière hospital, gastroenterology JIAN, Raymond; AP-HP HEGP, Gastroenterology Delchier, Jean-Charles; Hôpital Henri-Mondor, Hepatogastroenterology COFFIN, Benoît; AP-HP Hopital Louis Mourier, Gastroenterology Unit; Université Denis Diderot-Paris 7 Admane, Hakeem; Saint Antoine Hospital, Pharmacology, URCEST Carrat, Fabrice; Saint Antoine Hospital, Unit of public health Drouet, Elodie; Saint Antoine Hospital, Pharmacology, URCEST Beaugerie, Laurent; Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition</p>
Keywords:	Inflammatory bowel disease < Disease-based, Colonoscopy < Topics, Compliance / adherence < Topics, Colorectal cancer < Disease-based

1
2
3 **Low prevalence of colonoscopic surveillance of inflammatory bowel disease**
4
5 **patients with longstanding extensive colitis: a clinical practice survey nested in**
6
7 **the CESAME cohort**
8
9

10
11
12 **Running title: Colonoscopic surveillance in IBD**
13
14
15

16
17 Ariane Vienne,¹ Tabassome Simon,² Jacques Cosnes,¹ Clotilde Baudry,³ Yoram
18 Bouhnik,⁴ Jean Claude Soulé,⁵ Stanislas Chaussade,⁶ Philippe Marteau,⁷ Raymond
19 Jian,⁸ Jean-Charles Delchier,⁹ Benoît Coffin,¹⁰ Hakeem Admane,² Fabrice Carrat,¹¹
20 Elodie Drouet,² and Laurent Beaugerie,³
21
22
23
24
25
26
27
28

29 ¹ Department of Gastroenterology, AP-HP, Saint-Antoine Hospital F-75012 and UPMC Univ Paris 06 F-75005, Paris, France;

30 ²Department of Pharmacology, URC-EST, APHP, GH-STARTT, and UPMC Univ Paris 06, Paris, France; ³Department of
31 Gastroenterology, AP-HP, Saint-Louis Hospital F-75010 and Denis Diderot University, Paris 7, Paris, France; ⁴ Department of
32 Gastroenterology, AP-HP, Beaujon Hospital F-92110 and Denis Diderot University, Paris 7, Paris, France; ⁵Department of
33 Gastroenterology, AP-HP, Bichat Hospital F-75018 and Denis Diderot University, Paris 7, Paris, France; ⁶Department of
34 gastroenterology, AP-HP, Cochin Hospital F-75005 and Université Paris Descartes University, Paris, France; ⁷ Department of
35 Gastroenterology, AP-HP, Lariboisière Hospital F-75010 and Denis Diderot University, Paris 7, Paris, France; ⁸ Department of
36 gastroenterology, AP-HP, Hôpital Européen Georges Pompidou F-75015 and Université Paris Descartes, Paris, France; ⁹
37 Department of Gastroenterology, AP-HP, Henri Mondor Hospital and Univ Paris12 F-94000, Créteil, France; ¹⁰ Department of
38 Gastroenterology, AP-HP, Louis Mourier Hospital, Colombes, F-92700 and Denis Diderot University, Paris 7, Paris, France; ¹¹
39 Unit of Public Health, AP-HP, Saint-Antoine Hospital F-75012, INSERM UMR-S 707 F-75012 and UMR-S 707 UPMC Univ Paris
40 06 F-75012, Paris, France
41
42
43
44
45
46
47
48
49
50
51
52

53 **Correspondence:** Professor Laurent Beaugerie
54

55 Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, 184 rue du faubourg
56
57 Saint-Antoine, 75571 Paris CEDEX 12, France.
58

59 Tel: 33 1 49 28 31 71, Fax: 33 1 49 28 31 88 E-mail: laurent.beaugerie@sat.aphp.fr
60

Funding

This clinical practice study nested in the CESAME project was supported by an unconditional grant from Institut National du Cancer (INCa). The CESAME project was supported by grants from Programme Hospitalier de Recherche Clinique National (AOM05157), Association François Aupetit, Délégation Inter-régionale de la Recherche clinique Ile de France-Assistance Publique Hôpitaux de Paris (AP-HP), Ligue contre le Cancer, and Fonds de Recherche de la Société Nationale Française de Gastro-entérologie.

All the authors have nothing to disclose in relation with this work

AV, TS, FC, ED, HA and LB were involved in study concept and design. AV and LB were involved in drafting of the manuscript. All the authors were involved in acquisition and interpretation of data, and critical revision of the manuscript.

Abbreviations

5-ASA,5-amino-salicylates; CRC, Colorectal Cancer; IBD, Inflammatory Bowel Disease; UC, Ulcerative colitis

Crohn's disease

Abstract count word: 250

Acknowledgments

The authors wish to honor the memory of Marc Lémann who actively participated in the study

Summary

Background: Surveillance colonoscopy is recommended for inflammatory bowel disease (IBD) patients with longstanding extensive colitis (LEC).

Aims: To assess modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in university French hospitals.

Methods: Among 910 eligible patients with more than a 7-year history of extensive colitis at CESAME enrolment, 685 patients completed a questionnaire on surveillance colonoscopy and 102 were excluded because of prior proctocolectomy. Finally, 583 patients provided information spanning a median period of 41 months (IQR 38-43) between cohort enrolment and the end of follow-up. Details of the colonoscopic procedures and histological findings were obtained for 440 colonoscopies in 270 patients.

Results: Only 53.5% (n=312) of the patients with LEC had at least one surveillance colonoscopy during the study period, with marked variations across the 9 participating centres (27.3% to 70.0%, $p = < 0.0001$). Surveillance rate was significantly lower in Crohn's colitis than in ulcerative colitis (UC) (47.6% vs 68.5%, $p = < 0.0001$). Independent predictors of colonoscopic surveillance were male sex, UC IBD subtype, longer disease duration, previous history of CRC, and disease management in a centre with large IBD population. Random biopsies, targeted biopsies and chromoendoscopy were performed during respectively 70.7%, 26.6 and 30.0% of surveillance colonoscopies. Two cases of high-grade dysplasia were detected in patients undergoing colonoscopic surveillance. Two advanced-stage CRC were diagnosed in patients who did not have colonoscopic surveillance.

1
2
3 **Conclusions:** Colonoscopic surveillance rate is low in IBD patients with longstanding
4
5 extensive colitis.
6
7
8

9
10 **Key words:**
11

12 Inflammatory bowel disease; Colorectal cancer; Colonoscopic surveillance
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3 Patients with longstanding extensive ulcerative colitis (UC) are at high risk of
4 developing colonic epithelial dysplasia and carcinoma.¹ Growing evidence suggests
5 that the same is true of patients with longstanding extensive Crohn's colitis.^{2, 3} Two
6 interventions are currently used in an attempt to reduce mortality by colorectal cancer
7 (CRC) in these patients, namely colonoscopic surveillance and chemoprevention with
8 oral 5-aminosalicylates (5-ASA). Colonoscopic surveillance has not been shown to
9 reduce mortality among patients with extensive colitis, but it does tend to allow
10 cancer to be detected at an earlier stage, thereby improving the prognosis.⁴ There is
11 good international agreement that patients with inflammatory bowel disease (IBD)
12 and extensive colitis should have surveillance colonoscopy every 1-3 years, generally
13 starting 7-10 years after IBD onset, or from IBD diagnosis in patients with associated
14 primary sclerosing cholangitis.⁴⁻¹¹ Extensive UC is defined on the basis of the
15 cumulative macroscopic or microscopic extent of the disease proximal to the splenic
16 flexure.^{7, 12} Extensive Crohn's colitis is arbitrarily defined as cumulative endoscopic
17 involvement of more than one-third of the colon.^{2, 7} Surveillance colonoscopy should
18 ideally be performed outside periods of disease activity and with good bowel
19 cleansing, and should include multiple random biopsies or targeted biopsies after
20 chromoscopy.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Despite this solid consensus, questionnaire-based studies have revealed suboptimal
46 awareness and implementation of guidelines by gastroenterologists in various parts
47 of the world.^{13, 14} In addition, the degree of information, acceptance and adherence to
48 surveillance programs among patients at risk is unknown. Population-based studies
49 have shown poor implementation of endoscopic surveillance among IBD patients at
50 very high risk of colorectal cancer because of associated primary sclerosing
51 cholangitis.¹⁵ A low prevalence of colorectal surveillance of patients with longstanding
52
53
54
55
56
57
58
59
60

1
2
3 UC belonging to an integrated health care delivery system was recently reported,¹⁶
4
5 but there are no published reports of the implementation and yield of surveillance
6
7 colonoscopy in patients with either UC or Crohn's disease who are at a high risk of
8
9 colorectal cancer because of longstanding extensive colitis. We therefore conducted
10
11 an ancillary study nested in the CESAME project in order to assess the
12
13 implementation, modalities and yield of surveillance colonoscopy in a cohort of IBD
14
15 patients with longstanding extensive colitis. We also compared the incidence of
16
17 advanced-stage neoplasias in surveyed and non-surveyed patients, and examined
18
19 the relative proportions of patients receiving surveillance colonoscopy and/or
20
21 chemoprevention with 5-ASA.
22
23
24
25
26
27
28

29 **METHODS**

30 **Study design**

31
32 The study was nested in the CESAME project, which is described in detail
33
34 elsewhere.¹⁷ In brief, 19 486 IBD patients (1159 with Crohn's disease and 7727 with
35
36 UC or unclassified IBD) were enrolled between May 2004 and May 2005 in a French
37
38 nationwide cohort by 680 gastroenterologists, who reported all incident high-grade
39
40 dysplasias, cancers and deaths up to 31 December 2007. At enrolment, the
41
42 gastroenterologists recorded the patient's age, gender, IBD subtype, year of
43
44 diagnosis and cumulative extent of disease. Cumulative involvement of the colon in
45
46 UC and Crohn's colitis was arbitrarily categorized as extensive when the cumulative
47
48 percentage of the colonic surface ever involved, estimated by the investigating
49
50 gastroenterologist, exceeded 50%. CESAME patients meeting this criterion also
51
52 fulfilled the definition of extensive colitis stated in surveillance colonoscopy
53
54 guidelines.^{2, 7, 12}
55
56
57
58
59
60

1
2
3 This nested ancillary study was initiated in September 2008. Patients enrolled in the
4
5 CESAME cohort were eligible for this study if they belonged to the CESAME cohort
6
7 and met the following criteria: IBD duration longer than 7 years at the outset of the
8
9 CESAME observation period; extensive colitis at entry; and enrolment to the cohort
10
11 by a gastroenterologist working full-time in one of the 9 Paris area university hospital
12
13 gastroenterology units participating in the CESAME project. All 910 patients who met
14
15 these criteria were sent a questionnaire covering the following items: previous history
16
17 and type of any colectomy, current treatment with corticosteroids, thiopurines,
18
19 methotrexate or TNF antagonists, duration and modalities of any treatment with oral
20
21 5-ASA; and number of colonoscopies between May 2004 (first inclusions in the
22
23 CESAME cohort) and 31 December 2007. Patients who had at least one
24
25 colonoscopy were asked to complete an additional sheet for each colonoscopy,
26
27 covering where the colonoscopy was performed and the medical indication (flare,
28
29 disease assessment before a change of treatment, or cancer screening). The
30
31 questionnaire was accompanied by an explanatory letter and a pre-paid envelope to
32
33 return either the questionnaire or a refusal form. Patients who did not return the
34
35 completed questionnaire or the refusal form after one month were contacted by
36
37 telephone. If during the conversation they consented to participate, they were
38
39 interviewed by phone on the same items as those contained in the written
40
41 questionnaire. The protocol was approved by Comité Consultatif sur le Traitement de
42
43 l'Information en matière de Recherche dans le domaine de la Santé, and the study
44
45 was authorized (n° DR-2010-019) by Commission Nationale de l'Informatique et des
46
47 Libertés.
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient selection and analysis of colonoscopy reports

Among the 910 patients eligible for the study, 10 died before the questionnaires were sent out, and 34 had no known address (fig. 1). Eight hundred and sixty-six questionnaires were sent out. Nineteen patients refused to participate and 162 did not respond by mail or by phone. A total of 685 patients answered the questionnaire, representing a 79% participation rate. There was no statistically significant difference in gender, age or the IBD subtype between patients who answered the questionnaire and those who did not. Among the 685 patients who answered the questionnaire, 102 were excluded because of a prior history of proctocolectomy. The final study population consisted of 583 patients.

Among the 312 patients who mentioned at least one surveillance colonoscopy in the questionnaire, 282 had their examination performed in the endoscopy department of one of the nine participating centres. We were able to obtain a copy of the endoscopic and histological reports of 440 colonoscopies performed in 270 patients. A standardized report form was used to collect the following details: quality of bowel preparation (categorized as satisfactory or unsatisfactory); thoroughness of exploration of the colonic segments to be explored; presence of macroscopic inflammatory lesions (at least frank erythema); use of chromoscopy; and collection of random biopsies (at least 4 per segment) and/or targeted biopsies.

We were thus able to validate the information given by the patients on the number, indications and modalities of their colonoscopies, and found an overall concordance exceeding 90% for each item. In case of disagreement we kept the information contained in the endoscopic reports.

Data analysis

Taking into account the length of the study period (median 41 months, minimum 31 months) and published guidelines on surveillance colonoscopy, all the patients with longstanding extensive colitis should have had at least one surveillance colonoscopy, i.e. a dedicated cancer screening colonoscopy, during the study period. Patients who had at least one surveillance colonoscopy during the study period formed the “surveyed” population, and the remaining patients the “non-surveyed” population. Patients prescribed chemoprevention with 5-ASA during the study period formed the population of patients exposed to oral 5-ASA. Patients with unclassified IBD were pooled with UC patients for analysis.

Statview® statistical software (version 5.0, SAS Institute Inc., Cary, NC) was used to analyse the data. Fisher’s exact test was used to compare the proportions of surveyed and non-surveyed patients with each IBD subtype, and to identify a possible correlation between colonoscopic surveillance and 5-ASA chemoprevention.

The Chi-square test was used to compare the proportions of surveyed patients across the study centres. The following 8 variables were tested as possible independent predictors of colonoscopic surveillance: gender; IBD subtype; age; disease duration; previous personal history of colorectal cancer; sustained? treatment with 5-ASA; the number of IBD patients followed per investigator; and the number of IBD patients followed per centre. The 4 continuous variables were dichotomized around the median. All 8 variables were first separately compared between surveyed and non-surveyed patients by using Fisher’s exact test, then variables with p values below 0.20 were entered in a multivariate logistic regression model using a backward stepwise procedure. The final step retained independent factors with P values below 0.05 in a two-tailed test.

RESULTS

Overall surveillance rate and patients' baseline characteristics according to surveillance status

Characteristics of the 583 patients who answered the questionnaire by mail (n=351) or by phone (n=232) and who had no history of proctocolectomy are shown in table 1. The surveyed population consisted of 310 patients (53.2%) who had at least one surveillance colonoscopy during the study period (median 41, IQR 38-43). Respectively 165, 104, 33, 8 and 1 patients had 1, 2, 3, 4 and 5 surveillance colonoscopies. One patient had 7 surveillance endoscopies during the study period, to monitor unifocal low-grade dysplasia.

Factors influencing surveillance

The monitoring rate was significantly higher among patients with UC or unclassified IBD than among patients with Crohn's disease (68.5% versus 47.6%, $p < 0.0001$). Considering all IBD subtypes together, surveillance implementation varied widely across the study centres (27.3 to 70%, $p < 0.001$ (fig 2)). Independent predictors of surveillance (table 2) were male gender, UC, longer disease duration, a previous history of colorectal cancer, and management in a centre with a large IBD patient population.

Colonoscopic procedures and pathology reports:

We were able to analyze 440 reports of colonoscopies performed in 270 patients, along with the corresponding pathology reports. The quality of bowel preparation was specified in 82.7% of colonoscopy reports and was considered by the endoscopist as satisfactory and unsatisfactory in 83.8% and 16.2% of cases, respectively. Exploration of anatomically evaluable colonic segments was complete in 96.6% of

1
2
3 cases. Endoscopic evidence of mild inflammation (frank erythema or multiple
4
5 pseudopolyps) or active inflammation (ulceration) was mentioned in respectively
6
7 30.0% and 5.2% of reports. At least one biopsy was performed in 97.3% of
8
9 procedures, and consisted of random biopsies (at least 4 biopsy samples per colonic
10
11 segment), random biopsies plus targeted biopsies, or targeted biopsies alone, in
12
13 respectively 72.6%, 26.5% and 0.9% of cases. Chromoendoscopy was performed
14
15 during 30.0% of colonoscopies. The pathology reports mentioned the presence and
16
17 absence of active microscopic inflammation and any type of dysplasia in respectively
18
19 94.7% and 77.7% of cases. Fourteen cases of flat low-grade dysplasia were found in
20
21 12 patients (4.4%), of whom 5 were exposed to 5-ASA at the time of diagnosis of
22
23 dysplasia. Twelve adenoma-like masses with low-grade dysplasia were found in 11
24
25 patients (4%), of whom 6 were exposed to 5-ASA at the time of diagnosis of
26
27 dysplasia.
28
29
30
31
32
33
34
35

36 Incident advanced-stage neoplasias

37
38 Four patients in this ancillary study, all with Crohn's colitis, were diagnosed with
39
40 advanced-stage colonic neoplasia during the study period: two advanced-stage
41
42 colorectal cancers (T4N0M0 and T4N2M0) were diagnosed in non-surveyed patients.
43
44 The first patient was a 26-year man with a 10-year history of extensive Crohn's colitis
45
46 and the second a 30-year female with a 16-year history of extensive Crohn's colitis.
47
48 Two cases of high-grade dysplasia were detected in two surveyed patients. The first
49
50 patient was a 56-year man with a 10-year history of extensive Crohn's colitis and had
51
52 a flat dysplasia. The second patient was a 31-year man with a 15-year history of
53
54 extensive Crohn's colitis in whom a dysplasia-associated lesion or mass was
55
56 diagnosed. After confirmation of dysplasia by a second independent pathologist, both
57
58
59
60

1
2
3 patients underwent colectomy. Colon cancer was found on the colectomy
4
5 specimen of the **first** patient with flat high-grade dysplasia (stage T2N0M0). High-
6
7 grade dysplasia was confirmed on the colectomy specimen of the **second** patient with
8
9 the dysplasia-associated lesion or mass, without additional advanced-stage
10
11 neoplasia.
12
13
14
15
16
17
18
19

20 **Correlation between colonoscopic surveillance and chemoprevention with 5- 21 22 ASA**

23
24 Continuous oral 5-ASA was prescribed to 37.4% of the 583 patients during the study
25
26 period. The distribution of patients who received colonoscopic surveillance and/or
27
28 **treatment** with 5-ASA is shown in table 3 according to the IBD subtype. There was a
29
30 significant link between surveillance and **treatment with 5-ASA** ($p=0.0001$), with a
31
32 trend towards being either both **surveyed** and treated with 5-ASA, or **non-surveyed**
33
34 and untreated. When considering together the two types of IBD, one third of the
35
36 patients escaped both to endoscopic surveillance and **treatment with 5-ASA**.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

We observed **low** implementation of endoscopic surveillance in a cohort of IBD patients at high risk of colorectal cancer and managed in French university hospitals.

We also observed massive inter-centre variations and a large proportion of **non-surveyed** patients: one-third of patients with ulcerative colitis and more than one-half of patients with Crohn's colitis were not **surveyed**. Some cases of advanced colorectal neoplasias were diagnosed in **non-surveyed** patients.

This study was initially based on a self-reporting patient questionnaire, with a potential memory bias, representing therefore two important potential methodological limitations of the work. However, the completion rate of the questionnaire was 79% (81% when including patients who responded that they refused to participate), which is in the upper range of patient questionnaire ratings.¹⁸ The secondary exclusion of 11% of the patients because of previous proctocolectomy, thus with no actual eligibility for surveillance, did not impact on the quality of the results. Regarding memory bias, it is very unlikely that patients did not remember that they underwent one or several colonoscopies during the previous three years. We had also the opportunity through the study of endoscopic reports to validate the information given by the patients on the number, indications and modalities of their colonoscopies, and found an overall concordance exceeding 90% for each item. Finally, in the first author's centre, analysis of the local endoscopic files showed that surveillance was substantially less frequent among patients who did not answer the questionnaire (data not shown), suggesting that our results likely overestimate the implementation of endoscopic surveillance. So the main result of our work (low prevalence of surveillance) would have been amplified in the case of full completion rate of the questionnaire. We obtained details on colonoscopy in only 82% of surveyed patients,

1
2
3 but the main purpose of our study was not assess the yield of the surveillance
4 according to colonoscopy quality, and the number of detected neoplasias was too
5 low to properly assess the impact of different biopsy modalities or exposure to 5-ASA
6 on the rate of detected lesions.
7
8
9
10

11
12 In comparison with previous reports on the prevalence of colonoscopic surveillance in
13 IBD patients at risk for colorectal cancer,¹⁶ our study is the first to restrict the analysis
14 to patients at highest risk (i.e. with longstanding extensive colitis), to simultaneously
15 address the question patients with ulcerative colitis and Crohn's disease, and to give
16 the data on incident colorectal cancers in surveyed and non-surveyed patients.
17
18
19
20
21
22
23

24 Until now, information on gastroenterologists' adherence to international guidelines
25 on endoscopic surveillance of IBD patients at risk of colorectal cancer, and on the
26 management of dysplasia, has mainly been based on gastroenterologists' own
27 estimates.^{5, 14, 19, 20} The results of these studies showed that knowledge and
28 understanding of the pathogenesis and management of IBD-associated colorectal
29 neoplasias was unsatisfactory, but almost all the interviewed gastroenterologists
30 declared that they performed endoscopic surveillance in the majority of their IBD
31 patients at risk. Similarly, a clinical practice survey of patients already enrolled in
32 surveillance programs in a tertiary care centre suggested good implementation of
33 relevant guidelines.²¹
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 In order to obtain a more realistic view of the situation, we assessed the
49 implementation of surveillance colonoscopy by adopting an at-risk population-based
50 approach. Endoscopic surveillance has previously been shown to be suboptimal in a
51 subgroup of IBD patients at very high risk of colorectal cancer due to associated
52 primary sclerosing cholangitis.¹⁵ Likewise, a low rate of surveillance colonoscopy was
53
54
55
56
57
58
59
60

1
2
3 found in North California patients with at least an 8-year history of UC and belonging
4
5 to an integrated healthcare delivery organization.¹⁶
6
7

8 We based our study on the CESAME observational cohort, selecting patients at high
9
10 risk of colorectal cancer and managed in 9 university hospitals in the Paris area.
11
12 Implementation of endoscopic surveillance was found to be suboptimal, particularly in
13
14 Crohn's disease patients, even though all the participating centres belong to GETAID
15
16 and are therefore involved in promoting IBD education.
17
18

19
20 This **incomplete** endoscopic surveillance may be due to factors related to the patients
21
22 and/or their physicians. Patients may be reluctant to participate in surveillance
23
24 programs because they consider endoscopy to be unpleasant and risky, but UC
25
26 patients undergoing surveillance did not express increased anxiety or general health
27
28 impairment compared to a control population of UC patients.²² It is crucial to inform
29
30 IBD patients of the risk of CRC and the modalities and expected results of
31
32 surveillance. A survey conducted in the late 1990s suggested that patients were
33
34 adequately informed on the risk of colorectal cancer but not on the effectiveness and
35
36 modalities of surveillance programs,²³ including the safety of colonoscopy.²⁴ The
37
38 massive inter-centre variations observed in our study point rather to a role of
39
40 physician-related factors in suboptimal surveillance, and particularly poor awareness
41
42 of the benefits of surveillance.
43
44
45
46
47

48 Interestingly, the surveillance rate was higher among males than females in our
49
50 study, **while a similar non-significant trend towards a better surveillance in males was**
51
52 **reported in the study by Velayos et al.¹⁶ We have no explanation for that. In studies**
53
54 **assessing the predictors of participation in screening programs for sporadic colorectal**
55
56 **cancer, an increased prevalence of sigmoidoscopic surveillance²⁵ and a trend**
57
58
59
60

1
2
3 towards a preference for endoscopy rather than for faecal tests²⁶ were also reported
4
5 in males.
6

7
8 More than half the patients with extensive Crohn's colitis were not adequately
9
10 surveyed, whereas all the incident colorectal cancers were diagnosed in patients with
11
12 Crohn's disease. Inflammation-related cancers arising in Crohn's colitis and UC have
13
14 a similar distribution and histology (synchronous, right-sided, colloid contingent), and
15
16 tend to be associated with coexisting foci of flat dysplasia in both settings.^{27, 28} Similar
17
18 incidence rates of colorectal cancer have also been reported in UC and Crohn's
19
20 colitis,²⁷⁻³⁰ although this feature was restricted in some referral centre cohorts of
21
22 patients with Crohn's disease to those with UC-like lesions.³¹ In the CESAME
23
24 cohort, the rates of excess colorectal cancer were similar in UC and Crohn's disease
25
26 patients with longstanding extensive colitis.³ Thus, there is no theoretical reason to
27
28 adapt endoscopic surveillance to the IBD subtype. Published surveillance guidelines
29
30 refer currently to IBD colitis^{5-8, 10} or UC alone,⁹ but there are no statements on
31
32 colonoscopic surveillance in the most recent guidelines restricted to Crohn's
33
34 disease.³² Second, the definition of extensive Crohn's colitis^{2, 7} is not as consensual
35
36 as that of extensive UC and does not appear in the Montreal classification. Finally, it
37
38 may be more difficult to appreciate the cumulative percentage of inflamed mucosa in
39
40 multifocal Crohn's colitis than in UC-like Crohn's colitis or UC.
41
42
43
44
45
46

47
48 Chemoprevention is another approach to reducing the risk of colorectal cancer in
49
50 patients at risk, that has been considered by some authors as an alternative to
51
52 surveillance,³³ but we found that respectively 20% and 40% of UC and Crohn's
53
54 patients at risk escaped both control measures. The efficacy of treatment with 5-ASA
55
56 is controversial in IBD patients at risk, and especially those with Crohn's disease,
57
58 although the cost-effectiveness of combined methods has been recently estimated.³⁴
59
60

1
2
3 Whatever the final position of the gastroenterological community, the suboptimal and
4 highly variable implementation of both control methods observed here in real-life
5 practice is unacceptable and calls for urgent corrective measures. In addition to
6 better education of gastroenterologists and patients, elaboration of specific guidelines
7 in Crohn's disease, systematic mailing proposal for colonoscopic surveillance to
8 patients at risk, and greater implication of patient associations and health authorities
9 could be considered.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3 **Figure legends**
4
5
6
7

8 Figure 1. Flow chart
9

10
11
12
13
14
15 Figure 2. Proportion of IBD patients undergoing colonoscopic surveillance according
16
17 to IBD subtype (UC, ulcerative colitis; IBDU, IBD unclassified) and study centre
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;**48**:526-35.
2. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. *Clin Gastroenterol Hepatol* 2008;**6**:993-8.
3. Beaugerie L, Seksik P, Bouvier AM, et al. Thiopurine Therapy Is Associated with a Three-Fold Decrease in the Incidence of Advanced Colorectal Neoplasia in IBD Patients with Longstanding Extensive Colitis: Results from the CESAME Cohort. *Gastroenterology* 2009.;**136**:A-54.
4. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *Cochrane Database Syst Rev* 2006:CD000279.
5. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. *Gut* 2002;**51 Suppl 5**:V10-2.
6. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. *Gastroenterology* 2003;**124**:544-60.
7. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;**11**:314-21.
8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2004;**99**:1371-85.
9. Biancone L, Michetti P, Travis SP, et al. European evidence based consensus on the management of Ulcerative Colitis: special situations. *Journal of Crohn's and Colitis* 2008;**2**:63-92.
10. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut* 2010;**59**:666-89.
11. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 2010;**138**:738-45.
12. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006;**55**:749-53.
13. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. *Gastrointest Endosc* 2000;**51**:123-8.
14. Geary RB, Wakeman CJ, Barclay ML, et al. Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in New Zealand. *Dis Colon Rectum* 2004;**47**:314-22.
15. Kaplan GG, Heitman SJ, Hilsden RJ, et al. Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. *Inflamm Bowel Dis* 2007;**13**:1401-7.
16. Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. *Gastroenterology* 2010;**139**:1511-8.
17. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009;**374**:1617-25.
18. Richards SH, Campbell JL, Dickens A. Does the method of administration influence the UK GMC patient questionnaire ratings? *Prim Health Care Res Dev* 2011;**12**:68-78.

19. van Rijn AF, Fockens P, Siersema PD, et al. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. *World J Gastroenterol* 2009;**15**:226-30.
20. Thomas T, Nair P, Dronfield MW, et al. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. *Eur J Gastroenterol Hepatol* 2005;**17**:1317-24.
21. Kottachchi D, Yung D, Marshall JK. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. *Can J Gastroenterol* 2009;**23**:613-7.
22. Oxelmark L, Nordstrom G, Sjoqvist U, et al. Anxiety, functional health status, and coping ability in patients with ulcerative colitis who are undergoing colonoscopic surveillance. *Inflamm Bowel Dis* 2004;**10**:612-7.
23. Robinson RJ, Hart AR, Mayberry JF. Cancer surveillance in ulcerative colitis: a survey of patients' knowledge. *Endoscopy* 1996;**28**:761-2.
24. Koobatian GJ, Choi PM. Safety of surveillance colonoscopy in long-standing ulcerative colitis. *Am J Gastroenterol* 1994;**89**:1472-5.
25. Eloubeidi MA, Wallace MB, Desmond R, et al. Female gender and other factors predictive of a limited screening flexible sigmoidoscopy examination for colorectal cancer. *Am J Gastroenterol* 2003;**98**:1634-9.
26. Wong MC, Tsoi KK, Ng SS, et al. A comparison of the acceptance of immunochemical faecal occult blood test and colonoscopy in colorectal cancer screening: a prospective study among Chinese. *Aliment Pharmacol Ther* 2010;**32**:74-82.
27. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. *Gut* 1994;**35**:950-4.
28. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. *Histopathology* 2007;**50**:574-83.
29. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 1990;**323**:1228-33.
30. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. *Lancet* 1990;**336**:357-9.
31. Bergeron V, Vienne A, Sokol H, et al. Risk Factors for Neoplasia in Inflammatory Bowel Disease Patients With Pancolitis. *Am J Gastroenterol* 2010:advance online publication, 15 June 2010; doi: 10.1038/ajg.2010.248.
32. Van Assche G, Dignass A, Reinisch W. The second European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. *Journal of Crohn's and Colitis* 2010;**4**:63-88.
33. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000;**14**:145-53.
34. Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. *Am J Gastroenterol* 2009;**104**:2222-32.

Table 1 Characteristics of the study population (n=583) according to surveillance status during the study period

	Total (n=583)	Surveyed*(n=312)	Non-surveyed (n=271)
Male sex (%)	237 (40.6%)	143 (45.8%)	94 (34.7%)
Age at inclusion in the study †	40 (32-52)	41 (33-53)	38 (31-49)
IBD subtype			
Crohn's disease	418 (71.7%)	199 (63.8%)	219 (80.8%)
UC or IBD, unclassified	165 (28.3%)	113 (36.2%)	52 (19.2%)
IBD duration at inclusion (years)†	13.8(10.5-19.5)	14.9 (11.1-20.6)	12.6 (9.6-18.6)
Previous history of colorectal cancer	16 (2.7%)	15 (4.8%)	1 (0.3%)
Previous colectomy			
Segmental colectomy	92 (15.8%)	35 (11.2%)	57 (21%)
Subtotal colectomy	87 (14.9%)	44 (14.1%)	43 (15.9%)
Study period (months)†	41 (38-43)	41 (38-43)	42 (38-43)
Treatment at inclusion (%)			
Steroids	23 (3.9%)	11 (3.5%)	12 (4.4%)
Thiopurines or Methotrexate	227 (38.9%)	120 (38.5%)	107 (39.5%)
Anti-TNF	90 (15.4%)	41 (13.1%)	49 (18.1%)
Any oral 5-ASA throughout the study (%)	218 (37.4%)	139 (44.6%)	79 (29.1%)
Median dose of 5-ASA (g/day)†	2 (1.6-3)	2 (2-3)	2 (1.5-3)
Treatment duration with 5-ASA prior to the study (years) †	7 (1-15)	8 (2-16)	6 (1-14)

* At least one surveillance colonoscopy during the study period

† Median (IQR)

IBD, inflammatory bowel disease

Table 2. Independent predictors of colonoscopic surveillance

	Odds ratio	95% CI	p
Male sex	1.60	1.12-2.27	0.009
IBD subtype: UC+ IBDu	2.13	1.41- 3.22	0.0003
IBD duration at CESAME inclusion (per additional year)	1.04	1.01-1.07	0.009
Previous history of CRC	17.50	2.22-138.10	0.006
Large number of patients per centre (\geq 29 patients)	1.89	1.10-3.23	0.02

For Peer Review


Table 3. Distribution of the study population (n=583) according to colonoscopic surveillance status and treatment with any oral 5-ASA throughout the study period

	All patients (n= 583)		UC or IBD, unclassified (n=165)		Crohn's colitis (n= 418)	
	Surveyed (n=312)	Non-surveyed (n= 271)	Surveyed (n=113)	Non-surveyed (n= 52)	Surveyed (n= 199)	Non-surveyed (n= 219)
5-ASA (%*)	139 (23.8%)	79 (13.6%)	76 (46.1%)	22 (13.3%)	63 (15.1%)	57 (13.6%)
No 5-ASA (%)	173 (29.7%)	192 (32.9%)	37 (22.4%)	30 (18.2%)	136 (32.5%)	162 (38.8%)

* Percentages refer to the total of patients with the IBD subtype


For Peer Review

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EDITOR'S COMMENTS TO AUTHOR:

Very interesting (and worrying study). It would be interesting to know what "corrective measures" you would propose to implement.

Consider adding in the discussion a paragraph about strength and weaknesses of the study.

We added some suggestions for "corrective measures" in the last paragraph of the discussion. We also added two paragraphs in the discussion (second and third paragraph) considering the weaknesses and strengths of the work.

REVIEWERS' COMMENTS TO AUTHOR:

Reviewer: 1

Comments for Transmission to the Authors

Although AP&T discourages a geographical location in the Title, I think the country of the study should be mentioned in the Summary.

Done

AP&T has a specific style for the Summary: Background, Aim, Methods, Results, Conclusions - all in <250 words.

Done

In the past few years, AP&T has published several relevant papers about colonoscopy, which could augment the Discussion.

Two interesting papers from AP&T are now cited in the discussion

Reviewer: 2

Comments for Transmission to the Authors

In the present study the authors assessed modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of CRC.

The issue is an interesting one. Nevertheless, the main bias of the study is represented by the observation that a high proportion of patients were excluded from the analysis and that reports of colonoscopies were available only for a proportion of patients. The following major and minor issues should be addressed before acceptance of the manuscript.

Major comments

1. Study Population. Table 1 clearly shows that UC and CD patients were differently represented among monitored and unmonitored patients. In particular, in CD there was a higher proportion of unmonitored patients (81%)($p=?$). Moreover, the monitoring rate was higher in UC vs CD ($p<0.0001$)(pag. 10). This different distribution of patients may not allow proper comparison between CD and UC. Please discuss this finding.

We are not sure to have understood the reviewer's comment. May be there was an ambiguity in the "monitored" term so we replaced it by "surveyed". Regarding the completion rate of the questionnaire, there was no difference between Crohn's disease and ulcerative colitis. Among the patients finally studied, the surveillance rate was higher in ulcerative colitis than in Crohn's colitis, which is an important result of the study. The univariate statistical test was given in the text of the result section of the original version (first sentence of the paragraph entitled "factors influencing surveillance"). The role of the other factors on the surveillance rate was assessed by

1
2
3 *multivariate analysis (Table 2), which is the appropriate method to assess the*
4 *independent individual impact of other factors*
5
6
7

8 2. The proportion of patients assuming any oral 5-ASA was also higher in monitored
9 vs unmonitored patients (44.6% vs 29.1%; $p=?$). This observation may also
10 influence the rate of dysplastic/neoplastic lesions: please discuss this issue.

11 *The reviewer is right. We wrote in a dedicated paragraph of the result section of the*
12 *original manuscript that "There was a significant link between surveillance and*
13 *treatment with 5-ASA ($p=0.0001$), with a trend towards being either both surveyed*
14 *and treated with 5-ASA, or non-surveyed and untreated." The number of incident*
15 *neoplasias according to the exposure status to 5-ASA is now given in the revised*
16 *version of the manuscript. But we think that the influence of exposure to 5-ASA o the*
17 *incidence of neoplastic lesions cannot be properly assessed statistically given the low*
18 *number of events.*
19
20
21

22 3. Methods: page 7: 910 patients who met criteria were sent a questionnaire covering
23 several items regarding clinical characteristics of the disease. The bias of a
24 retrospective analysis reported in a questionnaire should be reported and discussed.

25 *Patients excluded for previous colectomy were not eligible for the study (no*
26 *colon, no surveillance), so this exclusion did not impact on the quality of the results.*
27 *The questionnaire completion rate was about 80% and there was no difference in the*
28 *completion rate according to IBD subtype (Method section). The memory bias is a*
29 *potential important one, but we had the opportunity to cross-validate self-reporting*
30 *data in the majority of the patients through the access to endoscopic reports. This is*
31 *discussed in the revised paper in the second and paragraph of the discussion.*
32
33
34

35 4. The major bias of the study is represented by the retrospective analysis of the data
36 and by the high rate of patients excluded from the analysis (from 910 to 583
37 patients). Moreover among these 583 patients, endoscopic reports were obtained
38 only for 440 colonoscopies performed in 270 patients. Details of colonoscopy
39 (including bowel preparation, reported only in 82% pts with endoscopic reports,
40 coecal intubation, etc were therefore missing in a high proportion of patients). Please
41 comment on that in the discussion.
42
43

44 5. The number and site of the biopsies differed among patients, thus leading to
45 possible differences in terms of diagnosis of dysplasia. Please comment on that.

46 *4 and 5. Our study was focused on the prevalence of the surveillance and the*
47 *identification of the factors associated with a low rate of surveillance. The reviewer is*
48 *right to point the incomplete data collection in the section of the work devoted to the*
49 *modalities of colonoscopies. So we chose not to speculate in the result or in the*
50 *discussion section on the relationship between colonoscopy modalities and incidence*
51 *of dysplastic lesion. In addition, the number of events was too low to perform an*
52 *accurate analysis.*
53
54

55 Minor comments

56
57 1. Figure 1: excluded due to "previous proctocolectomy" and not "colectomy", please
58 modify (page 8).

59 *Done*
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2. The percentage of patients not reporting the questionnaire but replying only by telephone should be reported in the results section and also discussed.

The number of patients contacted by phone was added in the revised manuscript. The questionnaire of the paper version and of the phone call was the same and the validity of declarative data is discussed in the second paragraph of the discussion.

3. Results regarding the detection of dysplasia (page 11) should be also reported in patients monitored vs unmonitored and in patients with vs without 5-ASA treatment.

In the non-surveyed (non-monitored) patients, only colorectal cancers were diagnosed. In the surveyed patients with incident dysplasia, we added the information on the proportion of patients exposed to 5-ASA.

4. Please provide clinical details of patients developing colorectal cancer and dysplasia (age, disease duration, use of 5-ASA, disease extent).

We provide in the revised version clinical details in all the patients who developed colorectal cancer or high-grade dysplasia.

Reviewer: 3

Comments for Transmission to the Authors

Beaugerie and colleagues performed a nested study within the CESAME cohort to assess use of surveillance colonoscopy in long-standing (>7 years) colitis (CD and UC). They

found that a significant number of pts did not have "adequate" surveillance. This analysis is of interest, not just because of the importance of the CESAME cohort and follow-up, but also because it contributes to the understanding that physicians are not performing surveillance as recommended in guidelines. The statement that the surveillance is "suboptimal" might be stretching it a bit, as we don't actually know what "optimal" surveillance really is - from a mortality benefit.

Additional strengths of the study includes that it reflects practice within the northern France gastro community, with a very high response rate to the surveys. In addition, there was a high degree of correlation b/w survey responses and chart review.

The concerns I raise include the following:

1. Can you really conclude that surveillance was "suboptimal" based on these results? I would suggest what you've shown is that surveillance is not following accepted guidelines in many patients, but to call it suboptimal suggests you've actually shown a significant difference in outcomes, which I don't think you have. If you were going to assess differences in outcomes of the monitored and unmonitored groups, you need to control for risks of neoplasia, including degree of inflammation, which is not captured in this database. Therefore, I'd suggest softening the conclusions and the title to more accurately reflect what is shown here- that guidelines are infrequently followed.

The reviewer is right. We replaced the term "suboptimal" with the more neutral term "low prevalence of".

2. What were the reasons for colectomy in the 102 patients who were eligible for this

1
2
3 study but couldn't participate? Were any of these due to dysplasia or cancer? If so,
4 that would suggest that there may be a survival bias or that the approach to
5 surveillance is more effective than acknowledged.

6
7 *Unfortunately, the indication of the proctocolectomy was not an item of the survey so*
8 *we have not this information.*
9

10 3. you refer to the patients on 5- ASA as having been "prescribed"
11 chemoprevention. Was that really the reason for it, or are you assuming so, but
12 actually the 5-ASA was being given for treatment? Consider modifying this language.

13 *The reviewer is right. We have no data on the indication of the treatment with 5-ASA.*
14 *We replaced the terms "chemoprevention" and "prescription" by "treatment with" and*
15 *"exposition".*
16
17

18 4. The group with previous colorectal cancer is of interest - if UC, would presume
19 that they had a proctocolectomy, so what exams were they receiving?? If CD, would
20 suspect that the area of colitis was resected in such patients, so perhaps they should
21 not have inflammation any longer (and might not undergo the usual surveillance)? I'd
22 suggest excluding these
23 patients from your analysis given the potential biases that they may cause.

24 *Patients with previous proctocolectomy were excluded from this work. The 14*
25 *patients with previous colorectal cancer (11 Crohn, 3 UC) had a segmental colectomy*
26 *or a subtotal colectomy with subsequent surveillance of the remaining segments.*
27 *They were better surveyed than the rest of the patient population (Table 3), which is*
28 *an interesting result. As we performed a multivariate analysis for assessing the other*
29 *factors, we are not sure that exclusion of patients with previous cancers is*
30 *appropriate.*
31
32
33

34 5. would be interesting to see the survey- perhaps as an online appendix

35 *The original survey was uploaded beside the manuscript.*
36
37

38 6. the gender differences (Males surveyed more than females) is fascinating and I
39 appreciate the discussion. Why? was their disease more active? is that what drove
40 this? (some gender based studies have shown that males are less likely to get
41 mucosal healing and other studies have shown that males are at higher risk for
42 cancer).

43 *We extended speculation and references on male predominance to other contexts of*
44 *colonoscopic surveillance.*
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SECCIRC

ENQUETE DE PRATIQUE DE LA COLOSCOPIE DANS LES MICI

NUMERO D'ANONYMAT

Vous vous apprêtez à répondre à un questionnaire dans le cadre d'une enquête sur la réalisation des coloscopies dans les MICI (Maladies Inflammatoires Chroniques de l'Intestin).
Un grand **MERCI** pour votre collaboration.

Pour toutes les questions suivantes, merci d'entourer la ou les réponses vous concernant :

A. De quel type de maladie inflammatoire de l'intestin souffrez-vous ?

0. Je ne sais pas
1. Recto-colite hémorragique (RCH)
2. Maladie de Crohn
3. Colite inflammatoire sans que l'on sache s'il s'agit d'une maladie de Crohn ou d'une RCH

B. Avez-vous déjà été opéré du côlon (gros intestin)

0. non, jamais
1. oui

C. * Si vous avez déjà été opéré du côlon (gros intestin), quel type d'opération avez-vous eue ?

0. on a enlevé tout le côlon et le rectum avec une anastomose iléo-anale et la confection d'un réservoir avec l'intestin grêle
1. on a enlevé tout le côlon et le rectum avec une poche définitive
2. on a enlevé tout le côlon mais pas le rectum
3. on a enlevé seulement une partie du côlon
4. je ne sais pas

** Si vous avez répondu 2, 3 ou 4 à la question précédente C, merci de répondre aux questions suivantes :*

** Si vous avez répondu 0 ou 1 à la question précédente C (ablation totale du côlon et du rectum), la question de la réalisation de coloscopies ne se pose pas de la même façon chez vous, **il n'est donc pas nécessaire que vous répondiez aux questions suivantes**. Merci d'avoir pris le temps de remplir et de nous renvoyer malgré tout ce questionnaire.*

1 D. Quel(s) traitement(s) recevez vous actuellement ? (plusieurs réponses possibles,
2 entourez les réponses exactes)
3

- 4 0. Je ne reçois actuellement aucun traitement
5 1. Comprimés (ou gélules ou granulés) de dérivés 5 aminosalicylés (5ASA) : Pentasa,
6 Rowasa, Dipentum, Fivasa ou Salazopyrine
7 2. Lavements de Pentasa ou de Quadrasa
8 3. Suppositoires de Pentasa, Rowasa, ou Fivasa
9 4. Comprimés de Cortisone : solupred, cortancyl, prednisone ou prednisolone
10 5. Imurel, Azathioprine, Purinethol, Méthotrexate
11 6. Remicade, Humira, Cimzia
12 7. Autre traitement pour la MICI: lequel.....
13
14
15
16

17 E. Si vous êtes actuellement traité par comprimés (ou gélules ou granulés) de
18 Pentasa, Rowasa, Dipentum, Fivasa ou Salazopyrine, depuis quand prenez vous ce
19 traitement de façon continue ? (mois et année ou année seule si vous ne vous
20 souvenez pas du mois)
21

- 22 0. Date de début du traitement.....
23 1. Je ne sais pas
24
25
26

27 F. Si vous êtes actuellement traité par comprimés (ou gélules ou granulés) de
28 Pentasa, Rowasa, Dipentum, Fivasa ou Salazopyrine, quelle dose prenez-vous
29 chaque jour ?
30

31 dose : (grammes/jour).....
32
33
34

35 G. Avez-vous eu des coloscopies entre le 01/05/2004 et la réception de ce courrier:
36

- 37 0. non
38 1. oui, une seule coloscopie
39 2. oui, 2 coloscopies
40 3. oui, plus de 2 coloscopies
41
42
43
44

45 Concernant les coloscopies réalisées entre le 01/05/2004 et la réception de ce courrier,
46 merci de répondre aux questions suivantes dans le tableau ci-joint en mettant une
47 croix dans la (ou les) case(s) correspondant à votre cas, comme dans l'exemple.
48
49
50

51 Merci de nous renvoyer ce questionnaire rempli à l'aide de l'enveloppe T ci jointe.

52 Vous pouvez également nous adresser ces éléments par fax au

53 Si vous avez des difficultés ou que vous préférez répondre à ce questionnaire par téléphone,
54 n'hésitez pas à nous appeler sur le numéro suivant : 01-49-28-22-02 afin que l'on puisse le remplir
55 avec vous par téléphone.
56

57 Afin de préserver votre anonymat, toutes les données vous concernant seront rendues anonymes
58

59 En vous remerciant du temps que vous nous avez consacré, soyez assuré(e), Madame, Monsieur,
60 de nos sentiments les plus cordialement dévoués.

L'équipe de l'étude SECCIRC

SECCIRC

ENQUETE DE PRATIQUE DE LA COLOSCOPIE DANS LES MICI
NUMERO D'ANONYMAT

		Exemple	Coloscopie N°1	Coloscopie N°2	Coloscopie N°3	Coloscopie N°4
Date de la coloscopie *	jj/mm/aaaa	01/05/2004				
Lieu de la coloscopie	Hôpital " nom de l'hôpital "	X				
	examen réalisé dans un autre établissement (autre hôpital ou cabinet privé)					
	je ne sais plus					
Raison de l'examen	poussée					
	bilan avant changement de traitement	X				
	dépistage					
	je ne sais pas					
Type de préparation	PEG: Kleanprep, Fortrans, Colopeg, Moviprep, Biopeg	X				
	Xprep					
	Fleetphosphosoda					
	je ne sais pas					

* Pour la date des coloscopies, si vous ne vous rappelez pas la date précise, merci de nous donner l'année et le mois